AstraZeneca Expansion Narrative: Widely Propagated, So the Edge Is Gone
The Opportunity
This is an edge-decay signal: the upstream bundle already contains multiple Tier-1 domains, and the signal is routed to the propagation monitor with an explicit edge-closing posture. The direction is effectively neutralised (FADE upstream) because the story has already moved into mainstream circulation, which is why it is AVOID here despite a clean ticker (AZN).
The Timing
With Bearish 72 market conditions, AZN can still move on macro and rates, but the specific informational advantage is not present in this workflow cycle. The only way this becomes interesting again is if a new, discrete expansion event appears with primary artefacts and a clear propagation gap; otherwise, this is already in consensus.
The Evidence
The upstream data explicitly flags Tier-1 presence (Bloomberg/Reuters/FT in the earlier bundle) and routes the signal as edge decaying. Hydrated evidence is missing in this run, so we cannot link the original articles; the correct takeaway is structural: the pipeline is telling you the information edge has already been competed away.